FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

Priority Review for Astellas NDA for AML Therapy

FDA accepts for priority review an Astellas Pharma NDA for gilteritinib for treating adult patients who have relapsed or refractory acute myeloid leuk...

Human Drugs

Adverse Event Submissions Clarified

FDA clarifies the submission process for expedited serious adverse event reports arising from ANDA BA/BE premarket studies.

Human Drugs

Pfizer Gains Breakthrough Status for Expanded Xalkori Uses

FDA grants Pfizer a Breakthrough Therapy designation for Xalkori (crizotinib) for treating patients with metastatic non-small cell lung cancer who hav...

Medical Devices

FDA Clears Lumendi 510(k) for Endoscopic Scissors

FDA clears a Lumendi 510(k) for the DiLumen Is Endolumenal Interventional Scissors, a sterile, single-use, disposable, monopolar electrosurgical devic...

Human Drugs

Europharma Concepts CGMP Violations

FDA warns Irelands Europharma Concepts about CGMP violations in its production of finished pharmaceuticals as a contract manufacturer.

Medical Devices

Lessons from FDA Multiple Function Device Guidance

Two Ropes & Gray attorneys highlight things learned from an FDA draft guidance on how FDA will regulate multiple function medical devices.

Medical Devices

FDA Reminds Surgical Staffs About Fire Risk

FDA reminds healthcare professionals working in surgical settings of the risk of surgical fires that can injure patients.

Human Drugs

cIAI Drug Development Guidance

FDA issues a guidance to assist in developing drugs to treat complicated intra-abdominal infections.

Medical Devices

FDA Soliciting Feedback on Software Products

FDA opens a docket to receive feedback on exclusion of certain medical software functions from agency regulation under the 21st Century Cures Act.

FDA General

Latest FDA Warning Letters

FDA releases its latest batch of Warning Letters that includes Europharma Concepts, Jalco Cosmetics and Jilin Shulan Synthetic Pharmaceutical.